IP Library Granted Patent US 7,695,731
Granted Patent B2
US 7,695,731 · App. 10/805,722 · Granted Apr 13, 2010

Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,695,731
App. No.
10/805,722
Granted
Apr 13, 2010
Kind
B2
Abstract

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

Claims (11)

1. A medical device comprising:

an implantable structure;

a basecoat matrix, including a combination of rapamycin and a cytostatic glucoside, in therapeutic dosages, incorporated in a first polymeric material, the basecoat matrix being affixed to the surface of the implantable medical device; and

a topcoat, including a second polymeric material, affixed to the basecoat matrix for controlling the elution rate of the rapamycin and the cytostatic glucoside.

2. The medical device according to claim 1 , wherein the cytostatic glucoside comprises etoposide.

3. The medical device according to claim 1 , wherein the implantable structure comprises a stent.

4. The medical device according to claim 1 , wherein the implantable structure comprises a stent-graft.

5. The medical device according to claim 1 , wherein the implantable structure comprises an anastomosis device.

6. The medical device according to claim 1 , wherein the second polymeric material is incompatible with the first polymeric material, thereby creating both a physical and chemical barrier to the elution of the rapamycin and the cytostatic glucoside.

7. The medical device according to claim 6 , wherein the first polymeric material comprises a fluoropolymer.

8. The medical device according to claim 7 , wherein the second polymeric material comprises an acrylic.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2007
From: CORDIS CORPORATION
To: WYETH
Reel/Frame 020234/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2004
From: FALOTICO, ROBERT; PARRY, TOM JAY; ZHAO, JONATHON Z.
To: CORDIS CORPORATION
Reel/Frame 015538/0158 →